Patrick John Finn Sells 2,311 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,311 shares of Twist Bioscience stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $37.13, for a total value of $85,807.43. Following the sale, the chief operating officer now directly owns 173,895 shares in the company, valued at approximately $6,456,721.35. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Patrick John Finn also recently made the following trade(s):

• On Tuesday, April 23rd, Patrick John Finn sold 2,174 shares of Twist Bioscience stock. The shares were sold at an average price of $30.12, for a total transaction of $65,480.88.
• On Tuesday, April 2nd, Patrick John Finn sold 492 shares of Twist Bioscience stock. The shares were sold at an average price of $32.74, for a total transaction of $16,108.08.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $41.40 on Thursday. The stock has a market cap of $2.41 billion, a price-to-earnings ratio of -12.32 and a beta of 1.64. The firm has a 50-day moving average of $34.18 and a two-hundred day moving average of $31.59. Twist Bioscience Co. has a 1 year low of $11.81 and a 1 year high of $44.92.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.05. The company had revenue of $75.30 million for the quarter, compared to analysts’ expectations of $70.70 million. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. Twist Bioscience’s revenue was up 25.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.06) earnings per share. Research analysts expect that Twist Bioscience Co. will post -3.17 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on TWST shares. The Goldman Sachs Group raised Twist Bioscience from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $25.00 to $45.00 in a report on Wednesday, January 17th. Evercore ISI boosted their price target on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Robert W. Baird lifted their price objective on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Barclays raised their price objective on Twist Bioscience from $40.00 to $45.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd. Finally, Scotiabank raised their price target on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research report on Monday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Twist Bioscience currently has an average rating of “Buy” and a consensus price target of $42.50.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its position in Twist Bioscience by 3.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,504 shares of the company’s stock valued at $8,965,000 after purchasing an additional 14,511 shares during the period. State Board of Administration of Florida Retirement System raised its stake in Twist Bioscience by 559.5% in the third quarter. State Board of Administration of Florida Retirement System now owns 106,572 shares of the company’s stock worth $2,159,000 after buying an additional 90,413 shares in the last quarter. Dark Forest Capital Management LP lifted its holdings in Twist Bioscience by 121.3% during the third quarter. Dark Forest Capital Management LP now owns 29,451 shares of the company’s stock worth $597,000 after buying an additional 16,142 shares during the period. Fox Run Management L.L.C. purchased a new position in shares of Twist Bioscience in the 3rd quarter valued at $451,000. Finally, Citigroup Inc. raised its position in shares of Twist Bioscience by 94.1% in the 3rd quarter. Citigroup Inc. now owns 264,204 shares of the company’s stock worth $5,353,000 after acquiring an additional 128,098 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.